维生素K拮抗剂与非维生素K拮抗剂口服抗凝药相关脑出血的临床与影像学特征
该回顾性研究分析了102例口服抗凝药相关的急性非创伤性脑出血患者,其中DOAC-ICH 25例、VKA-ICH 77例。两组入院血肿体积和血肿扩大均无显著差异(未校正p>0.05)。VKA-ICH中93.5%使用了靶向逆转策略,DOAC-ICH中仅8%。校正后,90天不良功能结局(改良Rankin量表评分4-6)与较低入院格拉斯哥昏迷评分(OR 1.63; 95%CI 1.26-2.10; p<0.001)和较大血肿体积(OR 1.03; 95%CI 1.00-1.05; p=0.046)独立相关。排除无随访头颅CT的患者后,VKA-ICH与不良90天结局的比值比约为3.5倍(OR 3.64; 95%CI 1.01-13.09; p=0.048),但全队列中口服抗凝药策略与90天结局无显著关联(OR 2.85; 95%CI 0.69-11.86; p=0.15)。结论提示DOAC并不导致更差的血肿扩大、血肿体积和功能结局,即使无靶向逆转策略可用,DOAC仍是VKA的安全替代选择。
要点
- DOAC-ICH与VKA-ICH的入院血肿体积和血肿扩大相似(未校正p>0.05)。
- VKA-ICH中93.5%使用靶向逆转策略,DOAC-ICH中仅8%。
- 校正后,较低入院GCS评分(OR 1.63; 95%CI 1.26-2.10; p<0.001)和较大血肿体积(OR 1.03; 95%CI 1.00-1.05; p=0.046)与90天不良功能结局独立相关。
- 排除无随访头颅CT的患者后,VKA-ICH与不良90天结局的OR为3.64(95%CI 1.01-13.09; p=0.048),但全队列中无显著关联(OR 2.85; 95%CI 0.69-11.86; p=0.15)。
- DOAC使用与更差的血肿扩大、血肿体积和功能结局无关,即使无靶向逆转策略可用,DOAC仍是VKA的安全替代选择。
适用人群与场景
- 口服抗凝药治疗相关的急性非创伤性脑出血患者,共102例(DOAC-ICH 25例,VKA-ICH 77例)。
处置流程与药物剂量
- VKA-ICH中93.5%使用了靶向逆转策略,DOAC-ICH中8%使用了靶向逆转策略。
研究设计与关键结果
- 回顾性分析102例口服抗凝药相关急性非创伤性脑出血患者,DOAC-ICH 25例,VKA-ICH 77例。
- DOAC-ICH与VKA-ICH的入院血肿体积和血肿扩大相似(未校正p>0.05)。
- 校正后,90天不良功能结局(改良Rankin量表评分4-6)与较低入院格拉斯哥昏迷评分(OR 1.63; 95%CI 1.26-2.10; p<0.001)和较大血肿体积(OR 1.03; 95%CI 1.00-1.05; p=0.046)独立相关。
- 排除无随访头颅CT的患者后,VKA-ICH与不良90天结局的OR为3.64(95%CI 1.01-13.09; p=0.048);全队列中口服抗凝药策略与90天结局无显著关联(OR 2.85; 95%CI 0.69-11.86; p=0.15)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- DOAC-ICH患者即使无靶向逆转策略可用,其血肿扩大、血肿体积和功能结局并不比VKA-ICH差,支持DOAC作为VKA的安全替代选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Recent studies indicated that functional outcome after intracranial hemorrhage (ICH) related to direct oral anticoagulation (DOAC-ICH) is similar, if not better, than vitamin K antagonist (VKA)-related ICH (VKA-ICH) due to a smaller initial hematoma volume (HV). However, the association with hematoma expansion (HE) and location is not well understood.
METHODS: We retrospectively analyzed 102 consecutive patients with acute non-traumatic ICH on oral anticoagulation therapy to determine HV and HE stratified by hematoma location, and the relation to the 90-day outcome.
RESULTS: DOAC-ICH (n = 25) and VKA-ICH (n = 77) had a similar admission HV and HE (unadjusted p > 0.05, each). Targeted reversal strategies were used in 93.5% of VKA-ICH versus 8% of DOAC-ICH. After adjustment, an unfavorable 90-day functional outcome (modified Rankin scale score 4-6) was independently associated with a lower admission Glasgow Coma Scale score (OR 1.63; 95% CI 1.26-2.10; p < 0.001) and greater HV (OR 1.03; 95% confidence interval (CI) 1.00-1.05; p = 0.046). After exclusion of patients without follow-up head computed tomography to allow for adjustment by occurrence of HE, VKA-ICH was associated with an approximately 3.5 times greater odds for a poor 90-day outcome (OR 3.64; 95% CI 1.01-13.09; p = 0.048). However, there was no significant association of the oral anticoagulant strategy with 90-day outcome in the entire cohort (OR 2.85; 95% CI 0.69-11.86; p = 0.15).
CONCLUSIONS: DOAC use did not relate to worse HE, HV, and functional outcome after ICH, adding to the notion that DOAC is a safe alternative to VKA even in the absence of access to targeted reversal strategies (which are still not universally available).
参考来源
- Miller MM, Lowe J, Khan M, et al. Clinical and Radiological Characteristics of Vitamin K Versus Non-Vitamin K Antagonist Oral Anticoagulation-Related Intracerebral Hemorrhage. Neurocrit Care. 2019. PMID: 30690686. doi:10.1007/s12028-019-00671-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。